MY PROSTATE SCORE 2.0
A LYNXDX INNOVATION

MyProstateScore 2.0

Next Generation of
Prostate Cancer Risk Assessment

MY PROSTATE SCORE 2.0
A LYNXDX INNOVATION

Comprehensive Array of Biomarkers

MPS2 is a urine test designed to predict the presence of clinically significant prostate cancer (Gleason score ≥7 or Grade Group ≥2) by analyzing a comprehensive array of 18 unique gene transcripts. Among the transcripts is the novel gene fusion, T2:ERG.

T2:ERG is an oncogenic fusion that results in androgen-driven cell proliferation, and is present in most men with prostate cancer. There is no biomarker more specific for prostate cancer.

By combining the specificity of the T2:ERG gene fusion with a supporting array of 17 other genetic biomarkers that characterize high-grade prostate cancer, MPS2 represents the next generation in prostate cancer risk prediction.

Flexible Algorithmic Analysis

The MPS2 algorithm has been developed to optimize diagnostic accuracy and provide clinical flexibility. MPS2 can be run as a biomarker-only test or inclusive of clinical risk factors, depending on provider preference.

18 Biomarkers

T2:ERG
SCHLAP1
OR51E2
APOC1
PCAT14
CAMKK2
PCA3
NKAIN1
B3GNT6

TFF3
SPON2
PCGEM1
TRGV9
TMSB15A
ERG
KLK3
KLK4
HOXC6

Optional Clinical Risk Factors

AGE

PSA OR PSAD

FAMILY HISTORY

ABNORMAL DRE

AFRICAN ANCESTRY

Best-in-Class Accuracy

The comprehensive array of biomarkers, robust analytical models, and clinical factor flexibility combine to create a test with best-in-class accuracy.

The accuracy of MPS2 is further tailored to specific patient cohorts through separate validation in biopsy naïve men and men with a prior negative biopsy.

When to Use MPS2

Eligibility Criteria If No Prior Biopsy

PSA	Patient Age	DRE Findings	MRI Status
3-10 ng/mL	≤75	Any	Any
<3 ng/mL	≤75	Abnormal	Any
4-10 ng/mL	>75	Any	Any
<4 ng/mL	>75	Abnormal	Any

Eligibility Criteria If Prior Negative Biopsy

| PSA	Patient Age	DRE Findings	MRI Status
3-10 ng/mL	≤75	Any	Any
<3 ng/mL	≤75	Abnormal	Any
4-10 ng/mL	>75	Any	Any
<4 ng/mL	>75	Abnormal	Any
>10 ng/mL	Any	Any	Negative (if performed)

Biopsy Naïve Men

up to 95% NPV

Biopsy naïve men with a low risk MPS2 result have a 93–95% probability that their biopsy will be negative for clinically significant prostate cancer (Gleason score ≥7 or Grade Group ≥2).

Men with a Prior Negative Biopsy

up to 99% NPV

Prior negative men with a low risk MPS2 result have a 98–99% probability that their biopsy will be negative for clinically significant prostate cancer (Gleason score ≥7 or Grade Group ≥2).

YOUR RESULTS
0-100%

Risk category: Low or Increasing

Likelihood of Clinically Significant Cancer Grade Group 2 or higher: 0-100%

Easy-to-Interpret Results

MPS2 results are available within 5-7 business days and report the percent likelihood that clinically significant prostate cancer would be detected on biopsy. The cutoff for low risk is dependent on clinical context and takes into consideration prior biopsy status and whether MPS2 is run as a biomarker-only test or inclusive of clinical risk factors.

Reimbursement Support

Lynx Dx is committed to helping patients access our testing services. If your patients need help navigating insurance coverage for MyProstateScore 2.0, our team is here to help.

Questions?

1-888-978-8MPS

or email us at clientservices@lynxdx.com

How to Order MyProstateScore 2.0

Contact

the Lynx Dx team at 1-888-978-8MPS or clientservices@lynxdx.com to have a Client Services representative provide you with the materials and information needed to get started.

Collect

post-DRE urine sample as indicated in the MPS2 specimen collection guide.

Complete

the Test Requisition Form and ship patient specimen to Lynx Dx.

Contact Us

Lynx Dx is committed to providing exceptional service for you and your patients. If you have questions or need assistance, our team is here to help.

Phone: 1-888-978-8677 / 1-888-978-8MPS

Email: clientservices@lynxdx.com | www.lynxdx.com